ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data.

ImmunoGen: Way Beyond SORAYA

It takes more than a price drop to make a bargain.

Is ImmunoGen Stock a Bargain After Dropping 39%?

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

Coinbase

Markets were jittery following troubling comments from Fed chair Jerome Powell.

Why Coinbase and Immunogen Led the Nasdaq Lower Monday

ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer patients, previously treated with Roche Holdings AG's (OTC: RHHBY) Avastin (bevacizumab). .

Why Are ImmunoGen Shares Trading Lower Today

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at Society of Gynecologic Oncology Annual Meeting

ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting

ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates.

ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q4 2021 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2021 Financial Results

ImmunoGen Reports Recent Progress and 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

Eli Lilly

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B

ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) directed to targets selected by Lilly based on ImmunoGen's camptothecin technology. Camptothecins are an important class of anticancer drugs targeting Type I topoisomerase.

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc. shares IMGN, -3.82% jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. LLY, -0.03% of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs.

ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs

ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs

The biotech company that focuses on oncology drugs released news from a positive clinical trial regarding its lead drug.

Why Shares of ImmunoGen Jumped 20.3% in December

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference

ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference

ImmunoGen is a turnaround stock that weathered the 2021 Biotech Bear market quite well. The lead medicine, mirvetuximab, recently demonstrated the robust data for the Phase 3 SORAYA trial.

ImmunoGen: Going Into A Transformative Year

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Initial Findings from Phase 1b/2 Study of IMGN632 in Combination with Vidaza® and Venclexta® in R/R Acute Myeloid Leukemia at ASH

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints. A pivotal confirmatory study using mirvetuximab, known as MIRASOL, is expected to have results out by Q3 of 2022. This confirmatory study is a crucial turning point for the company.

News for ImmunoGen Stock (IMGN)